SCHEMBL708419

SCHEMBL708419

CC(=O)Oc1cc2c(c(C)c1C)OC(C)(CCCC(C)CCCC(C)CCCC(C)C)CC2

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.71
KMT2A Q03164 2/20 0.71
PDE4A P27815 1/20 0.71
PDE3A Q14432 1/20 0.71
AKT1 P31749 6/20 0.69
PDPK1 O15530 2/20 0.62
PHLPP1 O60346 2/20 0.62
ILK Q13418 2/20 0.62
LMNA P02545 3/20 0.61
TTPA P49638 2/20 0.59
PSEN1 P49768 2/20 0.58
GSTO1 P78417 2/20 0.58
PTPN1 P18031 1/20 0.58
MAPT P10636 2/20 0.55
GSTP1 P09211 1/20 0.55
USP2 O75604 1/20 0.55
THRB P10828 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
ALOX5 P09917 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29390266 1.00 MEN1 (0.71) MEN1KMT2APDE4APDE3AAKT1
SCHEMBL708743 0.89 GSTO1 (0.74) MEN1KMT2APDE4APDE3AAKT1
SCHEMBL29959827 0.89 AKT1 (0.64) MEN1KMT2APDE4APDE3AAKT1
SCHEMBL4259671 0.87 AKT1 (0.91) MEN1KMT2APDE4APDE3AAKT1
SCHEMBL3241425 0.87 PSEN1 (0.72) MEN1KMT2APDE4APDE3AAKT1
SCHEMBL20635554 0.86 AKT1 (0.60) MEN1KMT2APDE4APDE3AAKT1
SCHEMBL14359795 0.86 AKT1 (0.60) MEN1KMT2APDE4APDE3AAKT1
SCHEMBL25118491 0.85 MEN1 (0.72) MEN1KMT2APDE4APDE3AAKT1
SCHEMBL708027 0.85 MEN1 (0.72) MEN1KMT2APDE4APDE3AAKT1
SCHEMBL8894988 0.85 GSTO1 (0.71) MEN1KMT2APDE4APDE3AAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116407543-A EPA-EE nano lipid composition, preparation method and application thereof 中国科学院上海药物研究所 2023-07-11 CN claimed
CN-110669255-A Stabilizer compositions containing substituted chroman compounds and methods of use thereof 塞特克技术公司 2020-01-10 CN claimed
US-9801913-B2 Barrier layer ATRIUM MEDICAL CORPORATION (US) 2017-10-31 US claimed
US-8821568-B2 Implant modified with non-hydroxylated vitamin D precursors NUMAT BIOMEDICAL S.L. (ES) 2014-09-02 US claimed
US-8795703-B2 Stand-alone film and methods for making the same ATRIUM MEDICAL CORPORATION (US) 2014-08-05 US claimed
US-8367099-B2 Perforated fatty acid films ATRIUM MEDICAL CORPORATION (US) 2013-02-05 US claimed
US-20130017234-A1 IMPLANT MODIFIED WITH NON-HYDROXYLATED VITAMIN D PRECURSORS NUMAT BIOMEDICAL S.L. (ES) 2013-01-17 US claimed
WO-2010104786-A1 USE OF CRYOGENIC PROCESSING TO OBTAIN A SUBSTANTIALLY-THICKENED FORMULATION ATRIUM MEDICAL CORPORATION (US) 2010-09-16 WO claimed
US-20100233231-A1 USE OF CRYOGENIC PROCESSING TO OBTAIN A SUBSTANTIALLY-THICKENED FORMULATION ATRIUM MEDICAL CORPORATION 2010-09-16 US claimed
EP-2086605-A2 PERFORATED BIOABSORBABLE OIL FILM AND METHODS FOR MAKING THE SAME Atrium Medical Corporation (US) 2009-08-12 EP claimed
WO-2008039308-A2 PERFORATED BIOABSORBABLE OIL FILM AND METHODS FOR MAKING THE SAME ATRIUM MEDICAL CORPORATION (US) 2008-04-03 WO claimed
EP-1812022-A2 STAND-ALONE FILM AND METHODS FOR MAKING THE SAME Atrium Medical Corporation (US) 2007-08-01 EP claimed
US-20070071798-A1 Perforated bioabsorbable oil film and methods for making the same ATRIUM MEDICAL CORPORATION (US) 2007-03-29 US claimed
US-20060088596-A1 Solubilizing a drug for use in a coating ATRIUM MEDICAL CORPORATION (US) 2006-04-27 US claimed
US-20060083768-A1 Method of thickening a coating using a drug ATRIUM MEDICAL CORPORATION (US) 2006-04-20 US claimed
WO-2006036984-A2 STAND-ALONE FILM AND METHODS FOR MAKING THE SAME ATRIUM MEDICAL CORPORATION (US) 2006-04-06 WO claimed
WO-2006036970-A2 METHOD OF THICKENING A COATING USING A DRUG ATRIUM MEDICAL CORPORATION (US) 2006-04-06 WO claimed
WO-2006036967-A1 SOLUBILIZING A DRUG FOR USE IN A COATING ATRIUM MEDICAL CORPORATION (US) 2006-04-06 WO claimed
US-20060067983-A1 Stand-alone film and methods for making the same ATRIUM MEDICAL CORPORATION (US) 2006-03-30 US claimed
US-6977269-B1 Method of improving animal tissue quality PIONEER HI-BRED INTERNATIONAL, INC (US) 2005-12-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100233231-A1 USE OF CRYOGENIC PROCESSING TO OBTAIN A SUBSTANTIALLY-THICKENED FORMULATION LIPA, CETP, CPT2 MEN1 2327/4885KMT2A 1477/4885PDE4A 1809/4885
US-20060083768-A1 Method of thickening a coating using a drug ABCB1, SLC10A2, ABCB11 MEN1 700/4885KMT2A 2668/4885PDE4A 1121/4885
US-20060088596-A1 Solubilizing a drug for use in a coating ABCB11, ABCB1, SLC10A2 MEN1 1118/4885KMT2A 3563/4885PDE4A 1289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.